From: Copeptin and risk stratification in patients with acute dyspnea
 | All patients | ADHF | No ADHF | |||
---|---|---|---|---|---|---|
Characteristic | HR for 30-day mortality | P -value | HR for 30-day mortality | P -value | HR for 30-day mortality | P -value |
Age (yr) | 1.05 (1.01 to 1.10) | 0.012 | 1.03 (0.98 to 1.09) | 0.230 | 1.06 (0.99 to 1.13) | 0.1 |
Male sex | 1.55 (0.73 to 3.27) | 0.255 | 1.59 (0.66 to 3.84) | 0.300 | 1.51 (0.36 to 6.33) | 0.57 |
BMI | 0.99 (0.93 to 1.05) | 0.68 | 1.01 (0.94 to 1.08) | 0.830 | 0.91 (0.80 to 1.04) | 0.18 |
Medical conditions (% of patients) | Â | Â | Â | Â | Â | Â |
   Heart failure | 1.40 (0.64 to 3.08) | 0.4 | 1.13 (0.48 to 2.69) | 0.780 | 0.05 (0.00 to 7228) | 0.61 |
   Coronary artery disease | 0.52 (0.20 to 1.35) | 0.18 | 0.47 (0.17 to 1.29) | 0.140 | 0.04 (0.00 to 127) | 0.43 |
   Chronic obstructive pulmonary disease | 0.47 (0.33 to 1.68) | 0.48 | 1.12 (0.44 to 2.89) | 0.810 | 0.46 (0.09 to 2.26) | 0.34 |
   Diabetes | 0.72 (0.25 to 2.06) | 0.53 | 0.50 (0.15 to 1.70) | 0.270 | 1.16 (0.14 to 9.40) | 0.89 |
   Hypertension | 0.77 (0.36 to 1.62) | 0.49 | 0.52 (0.21 to 1.28) | 0.150 | 0.80 (0.20 to 3.20) | 0.75 |
   Hyperlipidemia | 0.37 (0.13 to 1.06) | 0.07 | 0.32 (0.10 to 1.09) | 0.070 | 0.41 (0.05 to 3.34) | 0.41 |
   Chronic kidney disease | 2.89 (1.39 to 5.98) | 0.004 | 1.47 (0.62 to 3.46) | 0.380 | 9.64 (2.41 to 38.61) | 0.001 |
Initial clinical findings | Â | Â | Â | Â | Â | Â |
   Heart rate (bpm) | 1.01 (0.99 to 1.02) | 0.45 | 1.00 (0.98 to 1.02) | 0.870 | 1.02 (0.99 to 1.05) | 0.22 |
   Systolic pressure (mm Hg) | 0.97 (0.96 to 0.99) | < 0.001 | 0.98 (0.96 to 0.99) | 0.010 | 0.97 (0.94 to 1.00) | 0.02 |
   NYHA functional class | 3.44 (1.74 to 6.81) | < 0.001 | 7.47 (2.28 to 24.45) | 0.001 | 1.53 (0.65 to 3.67) | 0.33 |
   Edema | 1.73 (0.83 to 3.59) | 0.14 | 1.02 (0.43 to 2.42) | 0.960 | 3.00 (0.75 to 12.00) | 0.12 |
   Rales | 1.40 (0.66 to 2.95) | 0.38 | 0.72 (0.30 to 1.74) | 0.460 | 4.14 (0.84 to 20.53) | 0.08 |
Medication at admission | Â | Â | Â | Â | Â | Â |
   Beta-blockers | 0.82 (0.38 to 1.76) | 0.61 | 0.65 (0.28 to 1.53) | 0.320 | 0.04 (0.00 to 90) | 0.41 |
   ACE-Inhibitors/AT-receptor-blockers | 0.95 (0.46 to 1.96) | 0.88 | 0.51(0.22 to 1.20) | 0.120 | 1.96 (0.49 to 7.85) | 0.34 |
   Diuretics | 1.76 (0.82 to 3.79) | 0.15 | 1.40 (0.54 to 3.60) | 0.490 | 1.62 (0.41 to 6.49) | 0.49 |
Laboratory findings | Â | Â | Â | Â | Â | Â |
   eGFR - ml/minute/1.73m2 a | 0.11 (0.04 to 0.35) | < 0.001 | 0.18 (0.04 to 0.81) | 0.025 | 0.08 (0.01 to 0.55) | 0.011 |
   BNP a | 2.02 (1.14 to 3.58) | 0.017 | 1.23 (0.44 to 3.41) | 0.700 | 3.66 (0.83 to 16.11) | 0.086 |
   NT-proBNP a | 3.64 (2.02 to 6.56) | < 0.0001 | 4.57 (1.72 to 12.17) | 0.002 | 8.26 (2.34 to 29.12) | 0.001 |
   Copeptin a | 5.28 (3.08 to 9.06) | < 0.0001 | 5.36 (2.82 to 10.19) | < 0.001 | 4.21 (1.46 to 12.14) | 0.008 |